FTH

AI MemoPost-earnings T+3

Faeth Therapeutics

As of 2026-08-14/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 results reaffirm funded clinical timeline • 2026-08-04

Base target: $26 / p=50% prob

Biggest risk

The thesis remains binary and data-light: no efficacy readout is available, PIK-201 could disappoint, PIK-101 is early-stage, and Q2 R&D and G&A expenses rose to $9.2 million each. The deterministic prior is negative, supporting monitoring rather than aggressive positioning.

Invalidation

Break below $14 or thesis failure.

What would change my mind?

Faeth has a substantial post-financing cash position and two PIKTOR clinical programs, with the key Phase 2 endometrial-cancer readout expected by year-end 2026 and a second indication entering clinical development. [#SEC-8K-2026-08-04]

Research note

Recommendation

—

Confidence

medium

As of

2026-08-14

Base target

$26

p=50%

Bull target

$48

p=25%

Bear target

$14

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

PIK-101 breast-cancer development readout
Faeth has a substantial post-financing cash position and two PIKTOR clinical programs, with the key Phase 2 endometrial-cancer readout expected by year-end 2026 and a second indication entering clinical development.
[#SEC-8K-2026-08-04]

BearKey bullets

Binary efficacy and safety risk around the PIK-201 Phase 2 topline readout.
Future financing and capital-structure risk remain relevant despite the reported post-PIPE cash balance.
Low coverage: consensus surprise data, analyst revisions, options data, short interest, and independent market-reaction attribution are unavailable.

WatchKey bullets

Q2 results reaffirm funded clinical timeline

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $26 (p=50%)

Target spread vs base: +85% / -46%

Scenario probabilities

Bull Target: $48 (p=25%)Base Target: $26 (p=50%)Bear Target: $14 (p=25%)

Commentary

Post-earnings news tone is cautiously positive because management reaffirmed the year-end PIK-201 milestone, initiated PIK-101, and reported $186.4 million of cash. However, no trusted consensus comparison, analyst revisions, or post-print market-reaction attribution was available. Social and other sentiment fields are unavailable rather than neutral. The deterministic prior remains negative, with expected returns of -8.44% over 20 days and -17.73% over 120 days, so this remains a low-coverage, event-driven monitoring view.

As of 2026-08-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

PIK-101 breast-cancer development readout

Scenarios

Bull Target (Scenario probability)

$48 / p=25% prob

Base Target (Scenario probability)

$26 / p=50% prob

Bear Target (Scenario probability)

$14 / p=25% prob

Analysis 2026-08-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-04
Q2 results reaffirm funded clinical timeline
The Q2 release reported $186.4 million of cash, cash equivalents and marketable securities, reiterated year-end 2026 topline data for Phase 2 PIK-201, and confirmed first-patient dosing in Phase 1b/2 PIK-101. No consensus surprise was provided. [#SEC-8K-2026-08-04]
Prob 100.00% • Move 3.00% • Priced-in 80.00%
EVENT2026-12-31
PIK-201 Phase 2 endometrial-cancer topline data
Topline results from the Phase 2 PIK-201 trial are expected by year-end 2026. The outcome remains binary, with efficacy and safety data unavailable in the packet. [#SEC-8K-2026-08-04]
Prob 65.00% • Move 40.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

PIK-101 breast-cancer development readout
2027-12-31
PIK-101 is in Phase 1b/2 for HR+/HER2- advanced breast cancer, with initial safety and efficacy data expected in 2027. The program expands optionality but remains early-stage. [#SEC-8K-2026-08-04]
Prob 50% • Move 25% • Priced-in 20%

Risks

Binary efficacy and safety risk around the PIK-201 Phase 2 topline readout.
Future financing and capital-structure risk remain relevant despite the reported post-PIPE cash balance.
Low coverage: consensus surprise data, analyst revisions, options data, short interest, and independent market-reaction attribution are unavailable.
PIK-101 remains an early-stage program with initial data not expected until 2027.
Q2 R&D and G&A expenses increased materially, while cash runway cannot be independently estimated from the packet.

Peers

Symbol	Summary
BBOT	Same-sector, similar-market-cap biotechnology candidate; direct indication and program comparability are not established.
CTMX	Same-sector, similar-market-cap biotechnology candidate; useful as a loose reference only because direct clinical comparability is unconfirmed.
MNPR	Same-sector, similar-market-cap therapeutics candidate; limited basis for direct valuation comparison in the packet.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-14

Loading AI feed…

Symbol

Summary

BBOT

Same-sector, similar-market-cap biotechnology candidate; direct indication and program comparability are not established.

CTMX

Same-sector, similar-market-cap biotechnology candidate; useful as a loose reference only because direct clinical comparability is unconfirmed.

MNPR

Same-sector, similar-market-cap therapeutics candidate; limited basis for direct valuation comparison in the packet.